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Erythropoietin: not just 
about erythropoiesis
A paper by Sinclair and colleagues1 
in Blood challenges, on the basis of 
observations on cell lines, the concept 
that erythropoietin has activities 
unrelated to erythrodiﬀ erentiation. 
Sinclair and colleagues, based at 
Amgen, have published six papers 
since 2006 focused on whether the 
erythropoietin receptor (EPOR) is 
expressed by tumour cells—a fact 
that, if true, could have adverse 
eﬀ ects for the use of erythropoietin 
in cancer. They conclude that EPOR 
is not expressed by many of the 
cells previously reported to express 
EPOR and exhibit cytoprotection by 
erythropoietin, and question the entire 
concept that erythro poietin is active 
on non-haemopoietic cells.
Although sometimes data from 
one laboratory are not replicated in 
another, many investigators have 
reported trophic or antiapoptotic 
eﬀ ects of eryth ro poietin on many 
cells, including those that Sinclair 
and collea gues report in tabular form 
without presenting their original 
data. In fact, over the past 10 years, 
multiple investigators have shown that 
erythropoietin is tissue-protective, 
anti-inﬂ ammatory, and promotes 
neuro genesis and angio genesis.
The observation that erythro poietin 
is neuroprotective in vivo2 ignited 
substantial interest in its roles and 
possible therapeutic use in various 
diseases. Searching for “erythropoietin 
AND protect*”, PubMed gives 863 hits 
of which we identiﬁ ed 346 research 
papers reporting a protective or 
reparative action, and only ten a lack 
of extra-haemopoietic eﬀ ects.
Having no data to compare with 
previous studies, it is diﬃ  cult to 
under stand whether “inconsistent, 
irreproducible and at best modest 
(10–20%) eﬀ ects”1 refers to the 
inconsistency of the eﬀ ect or to 
Sinclair and colleagues’ experimental 
technique.
Sinclair and colleagues expand their 
conclusions further by stating that 
in vivo studies of erythropoietin in 
animal models of damage are faulty 
and that they “do not believe [that] 
clinical studies examining an alleged 
‘direct’ eﬀ ect of ESAs [erythropoiesis-
stimulating agents] on heart or brain 
function or repair are well founded”.1 
The term “alleged” is a hyperbole 
when referring to the tissue-
protective actions of erythropoietin 
that, independ ently of the receptors 
implicated, are supported by hundreds 
of studies, two meta-analyses,3,4 and 
some clinical trials, although we agree 
that caution should be used because 
of potential side-eﬀ ects.5
Cratylus, discussing with Plato, stated 
that names express the essence of the 
thing. This is hardly the case for cyto-
kines: look at tu mour necrosis factor 
or inter leukin 1. Although, from a 
pharma ceutical perspective, it would 
be con venient if erythropoietin had no 
activities outside erythropoiesis, this 
is wishful thinking. The ﬁ eld would be 
better served by eﬀ orts to understand 
the full spectrum of erythropoietin’s 
actions.
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